

# Heather A Jacene

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1037068/publications.pdf>

Version: 2024-02-01

65  
papers

7,056  
citations

279798

23  
h-index

144013

57  
g-index

66  
all docs

66  
docs citations

66  
times ranked

9064  
citing authors

#	ARTICLE	IF	CITATIONS
1	Imaging Androgen Receptors in Breast Cancer with <sup>18</sup> F-Fluoro-5 $\alpha$ -Dihydrotestosterone PET: A Pilot Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 22-28.	5.0	10
2	Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?. <i>Journal of Clinical Oncology</i> , 2022, 40, 3011-3014.	1.6	12
3	Imaging for Radiation Planning in Breast Cancer. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 542-550.	4.6	2
4	SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma. <i>Endocrine-Related Cancer</i> , 2022, 29, 533-544.	3.1	9
5	Evidence-Based Best Practices. <i>Clinical Nuclear Medicine</i> , 2021, 46, 569-570.	1.3	4
6	Correlation of <sup>68</sup> Ga-DOTATATE uptake on PET/CT with pathologic features of cellular proliferation in neuroendocrine neoplasms. <i>Annals of Nuclear Medicine</i> , 2021, 35, 1066-1077.	2.2	2
7	Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels. <i>Cancers</i> , 2021, 13, 2828.	3.7	8
8	Dermal Lymphatic Invasion, Survival, and Time to Recurrence or Progression in Inflammatory Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 449-455.	1.3	3
9	FDG PET for Assessment of Autologous Stem Cell Transplantation. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 380-391.	4.6	4
10	PET Imaging for Hematologic Malignancies. <i>Radiologic Clinics of North America</i> , 2021, 59, 705-723.	1.8	3
11	MRI Changes in Breast Skin Following Preoperative Therapy for Patients with Inflammatory Breast Cancer. <i>Academic Radiology</i> , 2021, , .	2.5	1
12	Intercostal Brown Adipose Tissue on FDG PET/CT. <i>American Journal of Roentgenology</i> , 2021, 217, 1007-1007.	2.2	1
13	Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns. <i>Journal of Nuclear Medicine</i> , 2021, 62, 23S-35S.	5.0	32
14	Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice. <i>Journal of Nuclear Medicine</i> , 2021, 62, 60S-72S.	5.0	19
15	Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana-Farber Cancer Institute's Inflammatory Breast Cancer Program experience. <i>Breast Journal</i> , 2020, 26, 384-390.	1.0	10
16	Computed tomographic assessment of lean body mass in patients on selective androgen receptor modulator. <i>Clinical Imaging</i> , 2020, 59, 100-103.	1.5	0
17	Extraprostatic Uptake of <sup>18</sup> F-Fluciclovine: Differentiation of Nonprostatic Neoplasms From Metastatic Prostate Cancer. <i>American Journal of Roentgenology</i> , 2020, 214, 641-648.	2.2	13
18	Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 383-390.	2.5	16

#	ARTICLE	IF	CITATIONS
19	2020 SNMMI Highlights Lecture: General Nuclear Medicine and Molecular Imaging. Journal of Nuclear Medicine, 2020, 61, 17N-23N.	5.0	0
20	No delayed imaging or CCK administration is needed in most cases when bowel excretion does not occur but gallbladder fills promptly. Annals of Nuclear Medicine, 2019, 33, 740-745.	2.2	0
21	Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. European Journal of Cancer, 2019, 114, 107-116.	2.8	42
22	Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade. Clinical Breast Cancer, 2019, 19, 146-155.	2.4	3
23	2019 SNMMI Highlights Lecture: General Nuclear Medicine and Molecular Imaging. Journal of Nuclear Medicine, 2019, 60, 13N-18N.	5.0	0
24	Hematologic Toxicity From Radium-223 Therapy for Bone Metastases in Castration-Resistant Prostate Cancer: Risk Factors and Practical Considerations. Clinical Genitourinary Cancer, 2018, 16, e919-e926.	1.9	14
25	Surveillance Imaging in Patients With Endometrial Cancer in First Remission. Current Problems in Diagnostic Radiology, 2018, 47, 311-316.	1.4	3
26	Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD two cycles followed by FDG-PET/CT restaging and 20 Gy of involved-site radiotherapy. Leukemia and Lymphoma, 2018, 59, 1384-1390.	1.3	7
27	PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up. Seminars in Nuclear Medicine, 2018, 48, 37-49.	4.6	28
28	Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. Melanoma Research, 2018, 28, 605-610.	1.2	24
29	Guidance on <sup>177</sup> Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division. Journal of Nuclear Medicine Technology, 2018, 46, 237-244.	0.8	19
30	Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Phase 2 Clinical Trials and Off-Trial Experience. Blood, 2018, 132, 145-145.	1.4	5
31	2018 SNMMI Highlights Lecture: General Nuclear Medicine. Journal of Nuclear Medicine, 2018, 59, 7N-13N.	5.0	0
32	Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors. New England Journal of Medicine, 2017, 376, 125-135.	27.0	2,206
33	The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer. Annals of Surgical Oncology, 2017, 24, 2563-2569.	1.5	26
34	Quantitation of Cancer Treatment Response by <sup>18</sup> F-FDG PET/CT: Multicenter Assessment of Measurement Variability. Journal of Nuclear Medicine, 2017, 58, 1429-1434.	5.0	11
35	Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy. Clinical Genitourinary Cancer, 2017, 15, e289-e298.	1.9	40
36	Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma. Molecular Imaging and Biology, 2017, 19, 429-436.	2.6	12

#	ARTICLE	IF	CITATIONS
37	Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. <i>Blood</i> , 2016, 128, 2489-2496.	1.4	370
38	Systemic Immune Response to Vaccination on FDG-PET/CT. <i>Nuclear Medicine and Molecular Imaging</i> , 2016, 50, 358-361.	1.0	28
39	Cancer Imaging at the Crossroads of Precision Medicine: Perspective From an Academic Imaging Department in a Comprehensive Cancer Center. <i>Journal of the American College of Radiology</i> , 2016, 13, 365-371.	1.8	12
40	Refractory myeloid sarcoma with a FIP1L1-PDGFR $\alpha$ rearrangement detected by clinical high throughput somatic sequencing. <i>Experimental Hematology and Oncology</i> , 2015, 4, 30.	5.0	6
41	Cancer Immunotherapy: Imaging Assessment of Novel Treatment Response Patterns and Immune-related Adverse Events. <i>Radiographics</i> , 2015, 35, 424-437.	3.3	161
42	Role of 2-Deoxy-2-[ <sup>18</sup> F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma. <i>PET Clinics</i> , 2015, 10, 207-225.	3.0	11
43	Inflammatory breast cancer and development of brain metastases: risk factors and outcomes. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 225-232.	2.5	29
44	Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management. <i>Annals of Surgical Oncology</i> , 2015, 22, 2483-2491.	1.5	26
45	Radionuclide Therapy for Osseous Metastases in Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 66-80.	4.6	21
46	Clinical practice patterns of Radium-223 (R223) utilization and variables associated with completion of therapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16076-e16076.	1.6	0
47	Gynecologic Oncologic Imaging With PET/CT. <i>Seminars in Nuclear Medicine</i> , 2014, 44, 461-478.	4.6	33
48	Postradiation Changes in Tissues. <i>PET Clinics</i> , 2014, 9, 217-235.	3.0	6
49	Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: A study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women's Cancer Center. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 592-599.	1.2	93
50	End-Therapy Positron Emission Tomography for Treatment Response Assessment in Follicular Lymphoma: A Systematic Review and Meta-analysis. <i>Clinical Cancer Research</i> , 2013, 19, 6566-6577.	7.0	21
51	Metabolic characterization of inflammatory breast cancer (IBC) with baseline FDG-PET/CT: Relationship with histopathology, hormone receptor status, and pathologic response after neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1105-1105.	1.6	14
52	Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. <i>Blood</i> , 2012, 119, 4129-4132.	1.4	67
53	Positron emission tomography/computed tomography to improve staging and restaging in Merkel cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8552-8552.	1.6	0
54	<sup>18</sup> F-FDG PET/CT for Monitoring the Response of Lymphoma to Radioimmunotherapy. <i>Journal of Nuclear Medicine</i> , 2009, 50, 8-17.	5.0	66

#	ARTICLE	IF	CITATIONS
55	Assessment of Interobserver Reproducibility in Quantitative 18F-FDG PET and CT Measurements of Tumor Response to Therapy. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1760-1769.	5.0	65
56	From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors. <i>Journal of Nuclear Medicine</i> , 2009, 50, 122S-150S.	5.0	3,047
57	Scalene muscle uptake: a potential pitfall in head and neck PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 89-94.	6.4	20
58	Comparison of Residence Time Estimation Methods for Radioimmunotherapy Dosimetry and Treatment Planning—Monte Carlo Simulation Studies. <i>IEEE Transactions on Medical Imaging</i> , 2008, 27, 521-530.	8.9	48
59	Phase I/II Dose-Escalation Study of Tositumomab and Iodine I 131 Tositumomab for Relapsed/Refractory Classical or Lymphocyte-Predominant Hodgkin's Lymphoma: Feasibility and Initial Safety. <i>Blood</i> , 2008, 112, 3059-3059.	1.4	7
60	Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1767-1776.	5.0	81
61	Lymphadenopathy Resulting From Acute Hepatitis C Infection Mimicking Metastatic Breast Carcinoma on FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2006, 31, 379-381.	1.3	27
62	Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies. <i>Journal of Nuclear Medicine</i> , 2006, 47, 950-6.	5.0	43
63	Imaging of Pelvic Malignancies with In-Line FDG PET-CT: Case Examples and Common Pitfalls of FDG PET. <i>Radiographics</i> , 2005, 25, 1031-1043.	3.3	143
64	2-deoxy-2-[F] fluoro-D-glucose uptake in intercostal respiratory muscles on positron emission tomography/computed tomography: smokers versus nonsmokers. <i>Molecular Imaging and Biology</i> , 2004, 6, 405-410.	2.6	6
65	F-18 FDG PET/CT in Acute Respiratory Distress Syndrome: A Case Report. <i>Clinical Nuclear Medicine</i> , 2004, 29, 786-788.	1.3	16